Neuraxis financials
$7.76+4.86%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $3.6M | $2.7M | $2.5M |
| Gross profit | $3.0M | $2.3M | $2.2M |
| Gross margin | 84.2% | 86.5% | 87.7% |
| Operating income | -$7.8M | -$7.2M | -$6.7M |
| Net income | -$8.6M | -$8.5M | -$14.6M |
| Net margin | −241.4% | −314.7% | −594.6% |
| Diluted EPS | $-0.95 | $-1.22 | $-4.50 |
| EBITDA | -$7.8M | -$7.1M | -$6.6M |
| Operating cash flow | -$6.4M | -$6.1M | -$6.7M |
| Free cash flow | -$6.5M | -$6.1M | -$6.7M |
| Diluted shares | 9.1M | 6.9M | 3.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $5.0M | $3.7M | $78.6K |
| Short-term investments | $0.00 | $0.00 | $0.00 |
| Total debt | $148.3K | $154.2K | $148.1K |
| Total assets | $6.4M | $4.8M | $509.5K |
| Total liabilities | $3.0M | $2.7M | $1.9M |
| Shareholders' equity | $3.4M | $2.1M | -$1.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology